Welcome to our dedicated page for WORK Medical Technology Group news (Ticker: WOK), a resource for investors and traders seeking the latest updates and insights on WORK Medical Technology Group stock.
WORK Medical Technology Group LTD (Nasdaq: WOK) is a medical devices company that develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through subsidiaries in China. Its news flow, as reflected in company press releases and SEC reports, spans product development, regulatory milestones, capital markets activity, and strategic collaborations.
Readers following WOK news can track updates on WORK Medical’s portfolio of medical consumables, including customized and multifunctional masks and other disposable devices, as well as its expansion into AI-enabled diagnostic equipment. A key recent theme is the company’s AI-Automated Human Blood Cell Morphology Analyzer, a Class II medical device developed by subsidiary Hunan Saitumofei. News items cover manufacturing approval from a Chinese regulatory authority, technical capabilities of the analyzer, and an exclusive distribution agreement with Shanghai Benke Medical Technology Co., Ltd. for East China.
WORK Medical’s news also includes announcements on equity investments and partnerships. The company has reported a 10% equity investment in Neologics Bioscience Inc., a Delaware-based medical technology firm focused on integrating artificial intelligence and medicine, and subsequent service agreements between Neologics and GemPharmatech Corporation. In addition, WORK Medical has disclosed a strategic cooperation agreement with Hong Kong Web3.0 Standardization Association Limited to explore blockchain and Real-world Asset technology applications.
Capital markets and listing-related developments form another important category of WOK news. The company has issued press releases on registered direct offerings, at-the-market offering arrangements, reverse stock splits, and communications from Nasdaq regarding minimum bid price compliance and potential delisting determinations. For investors and observers, the WOK news page on Stock Titan provides a centralized view of these disclosures, helping users review product, regulatory, financing, and governance announcements in one place.
WORK Medical Technology Group (Nasdaq: WOK) will effect a 1-for-100 reverse stock split effective October 21, 2025, with Class A shares trading on a post-split basis from market open that day under the existing ticker WOK and new CUSIP G9767H117.
The split was approved by shareholders and the board to regain compliance with Nasdaq Rule 5550(a)(2). Fractional shares will be rounded up to the next whole share. Outstanding Class A shares will fall from approximately 96.00 million to 960,000; Class B shares will fall from approximately 7.59 million to 76,000.
WORK Medical Technology Group (NASDAQ: WOK) received a Nasdaq determination letter dated October 9, 2025 notifying the company of a delisting due to its Class A ordinary shares having a closing bid price of $0.10 or less for ten consecutive trading days ending October 8, 2025.
Unless appealed, trading will be suspended at the open of business on October 20, 2025 and a Form 25-NSE will be filed to remove the company’s securities from Nasdaq. The company may request a hearing by October 16, 2025; a hearing request will stay the suspension. The company plans to appeal by October 16 and said it will consider options to regain compliance, including a possible reverse share split.
WORK Medical (Nasdaq: WOK) received a Nasdaq notification dated October 7, 2025 granting an additional 180-calendar-day compliance period to regain the minimum bid price under Nasdaq Listing Rule 5550(a)(2).
The company’s initial 180-day cure period expired October 6, 2025; the new deadline is April 6, 2026. To regain compliance, WOK must achieve a closing bid of $1.00 per share for at least 10 consecutive business days (Nasdaq may require up to 20 days depending on factors).
The company said it intends to cure the deficiency, including potentially implementing a reverse stock split. Trading of Class A ordinary shares on Nasdaq under WOK continues with no immediate delisting action.
WORK Medical Technology Group (NASDAQ:WOK) has announced a registered direct offering of 38,999,334 Class A ordinary shares at $0.075 per share, aiming to raise approximately $2.9 million in gross proceeds. The offering includes pre-funded warrants with an exercise price of $0.0005 per share.
The transaction, expected to close around September 26, 2025, is being conducted under a shelf registration statement on Form F-3. Univest Securities, LLC is serving as the sole placement agent for this offering.
WORK Medical Technology Group (NASDAQ:WOK) has announced a strategic partnership with the Hong Kong Web3.0 Standardization Association Limited to innovate in blockchain and Real-world Asset (RWA) solutions. The collaboration focuses on three key areas: asset tokenization, joint investment vehicles, and RWA technology development.
As part of the agreement, WORK Medical has been appointed as a Vice President Unit of the Association. The partnership aims to leverage WORK Medical's status as a Nasdaq-listed medical device manufacturer and the Association's Web3.0 expertise to develop compliant blockchain solutions for asset tokenization and cross-chain transactions.
WORK Medical Technology Group (NASDAQ:WOK) has announced a strategic partnership with the Wuxi Branch of Ruijin Hospital-Shanghai Jiao Tong University School of Medicine (Xin Rui Hospital) to develop AI-powered medical solutions. Through its subsidiary Work Hangzhou, the company will support Xin Rui Hospital in advancing hospital informatization and AI applications.
The collaboration aims to integrate AI technology with Xin Rui Hospital's multimodal medical resources, including text, imaging, and laboratory data. Work Hangzhou plans to enhance its multimodal universal medical AI solution by expanding from single-image data to complex multimodal data. The partnership will focus on data governance, model training, and clinical practice implementation.
WORK Medical Technology Group (Nasdaq: WOK) has successfully closed its registered offering of 10 million ordinary units at $0.50 per unit, raising gross proceeds of $5.0 million. Each unit includes one Class A ordinary share and two warrants (Series A and B) to purchase additional shares at $1.00 exercise price. Series A warrants expire in 12 months, while Series B warrants expire in 3 months.
The company plans to use the proceeds for upgrading production equipment, R&D investments, improving internal control systems, ensuring compliance with U.S. GAAP and Sarbanes-Oxley Act, and working capital. Univest Securities served as the sole book-running manager for this firm commitment offering.
WORK Medical Technology Group (Nasdaq: WOK) has received a notification from Nasdaq on April 7, 2025, indicating non-compliance with the minimum bid price requirement. The company's stock failed to maintain the required $1.00 per share minimum bid price for 30 consecutive business days from February 24 to April 4, 2025.
The company has been granted a 180-day compliance period until October 6, 2025, to meet the minimum bid price requirement. To regain compliance, WOK's shares must maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. If unsuccessful, the company may face potential delisting, though it may be eligible for additional time.
WORK Medical is considering various options, including a potential reverse share split, to address this deficiency. The company's business operations remain unaffected by this notification.
WORK Medical Technology Group (Nasdaq: WOK), a medical device supplier operating through its subsidiary Work (Hangzhou) Medical Treatment Equipment Co. in China, has announced the implementation of a dual-class share structure. The new share structure will take effect on March 6, 2025.